vs
Side-by-side financial comparison of Acadia Healthcare Company, Inc. (ACHC) and AVANOS MEDICAL, INC. (AVNS), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Acadia Healthcare Company, Inc. is the larger business by last-quarter revenue ($821.5M vs $180.9M, roughly 4.5× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -143.3% vs -0.7%, a 142.6% gap on every dollar of revenue. On growth, Acadia Healthcare Company, Inc. posted the faster year-over-year revenue change (6.1% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-179.5M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 3.4%).
Acadia Healthcare Company, Inc. is an American provider of for-profit behavioral healthcare services. It operates a network of over 225 facilities across the United States and Puerto Rico.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
ACHC vs AVNS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $821.5M | $180.9M |
| Net Profit | $-1.2B | $-1.3M |
| Gross Margin | — | 47.5% |
| Operating Margin | -142.4% | 1.4% |
| Net Margin | -143.3% | -0.7% |
| Revenue YoY | 6.1% | 0.7% |
| Net Profit YoY | -3710.4% | 99.7% |
| EPS (diluted) | $-12.98 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $821.5M | $180.9M | ||
| Q3 25 | $851.6M | $177.8M | ||
| Q2 25 | $869.2M | $175.0M | ||
| Q1 25 | $770.5M | $167.5M | ||
| Q4 24 | $774.2M | $179.6M | ||
| Q3 24 | $815.6M | $170.4M | ||
| Q2 24 | $796.0M | $171.7M | ||
| Q1 24 | $768.1M | $166.1M |
| Q4 25 | $-1.2B | $-1.3M | ||
| Q3 25 | $36.2M | $-1.4M | ||
| Q2 25 | $30.1M | $-76.8M | ||
| Q1 25 | $8.4M | $6.6M | ||
| Q4 24 | $32.6M | $-397.3M | ||
| Q3 24 | $68.1M | $4.3M | ||
| Q2 24 | $78.5M | $1.8M | ||
| Q1 24 | $76.4M | $-900.0K |
| Q4 25 | — | 47.5% | ||
| Q3 25 | — | 48.4% | ||
| Q2 25 | — | 52.6% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 54.6% | ||
| Q3 24 | — | 54.5% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 57.1% |
| Q4 25 | -142.4% | 1.4% | ||
| Q3 25 | 4.7% | 0.1% | ||
| Q2 25 | 5.8% | -42.6% | ||
| Q1 25 | 1.7% | 6.1% | ||
| Q4 24 | 4.9% | -233.0% | ||
| Q3 24 | 12.1% | 7.0% | ||
| Q2 24 | 13.4% | 3.7% | ||
| Q1 24 | 12.9% | 2.4% |
| Q4 25 | -143.3% | -0.7% | ||
| Q3 25 | 4.3% | -0.8% | ||
| Q2 25 | 3.5% | -43.9% | ||
| Q1 25 | 1.1% | 3.9% | ||
| Q4 24 | 4.2% | -221.2% | ||
| Q3 24 | 8.4% | 2.5% | ||
| Q2 24 | 9.9% | 1.0% | ||
| Q1 24 | 9.9% | -0.5% |
| Q4 25 | $-12.98 | $-0.02 | ||
| Q3 25 | $0.40 | $-0.03 | ||
| Q2 25 | $0.33 | $-1.66 | ||
| Q1 25 | $0.09 | $0.14 | ||
| Q4 24 | $0.36 | $-8.64 | ||
| Q3 24 | $0.74 | $0.09 | ||
| Q2 24 | $0.85 | $0.04 | ||
| Q1 24 | $0.83 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.2M | $89.8M |
| Total DebtLower is stronger | $2.5B | $90.3M |
| Stockholders' EquityBook value | $1.9B | $778.2M |
| Total Assets | $5.5B | $1.1B |
| Debt / EquityLower = less leverage | 1.28× | 0.12× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $133.2M | $89.8M | ||
| Q3 25 | $118.7M | $70.5M | ||
| Q2 25 | $131.4M | $90.3M | ||
| Q1 25 | $91.2M | $97.0M | ||
| Q4 24 | $76.3M | $107.7M | ||
| Q3 24 | $82.1M | $89.0M | ||
| Q2 24 | $77.2M | $92.2M | ||
| Q1 24 | $77.3M | $75.8M |
| Q4 25 | $2.5B | $90.3M | ||
| Q3 25 | $2.3B | $93.4M | ||
| Q2 25 | $2.3B | $95.7M | ||
| Q1 25 | $2.2B | $98.0M | ||
| Q4 24 | $2.0B | $125.3M | ||
| Q3 24 | $1.9B | $152.6M | ||
| Q2 24 | $1.8B | $164.9M | ||
| Q1 24 | $1.9B | $167.2M |
| Q4 25 | $1.9B | $778.2M | ||
| Q3 25 | $3.1B | $778.0M | ||
| Q2 25 | $3.1B | $776.3M | ||
| Q1 25 | $3.0B | $839.4M | ||
| Q4 24 | $3.1B | $828.5M | ||
| Q3 24 | $3.0B | $1.2B | ||
| Q2 24 | $3.0B | $1.2B | ||
| Q1 24 | $2.9B | $1.2B |
| Q4 25 | $5.5B | $1.1B | ||
| Q3 25 | $6.4B | $1.1B | ||
| Q2 25 | $6.3B | $1.0B | ||
| Q1 25 | $6.1B | $1.1B | ||
| Q4 24 | $6.0B | $1.2B | ||
| Q3 24 | $5.9B | $1.7B | ||
| Q2 24 | $5.7B | $1.7B | ||
| Q1 24 | $5.5B | $1.7B |
| Q4 25 | 1.28× | 0.12× | ||
| Q3 25 | 0.74× | 0.12× | ||
| Q2 25 | 0.74× | 0.12× | ||
| Q1 25 | 0.72× | 0.12× | ||
| Q4 24 | 0.64× | 0.15× | ||
| Q3 24 | 0.62× | 0.12× | ||
| Q2 24 | 0.62× | 0.13× | ||
| Q1 24 | 0.65× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-86.3M | $28.2M |
| Free Cash FlowOCF − Capex | $-179.5M | $21.3M |
| FCF MarginFCF / Revenue | -21.8% | 11.8% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 11.3% | 3.8% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-439.9M | $43.1M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $-86.3M | $28.2M | ||
| Q3 25 | $73.2M | $14.0M | ||
| Q2 25 | $133.5M | $6.8M | ||
| Q1 25 | $11.5M | $25.7M | ||
| Q4 24 | $116.7M | $57.9M | ||
| Q3 24 | $163.1M | $23.0M | ||
| Q2 24 | $171.1M | $27.8M | ||
| Q1 24 | $-321.3M | $-8.0M |
| Q4 25 | $-179.5M | $21.3M | ||
| Q3 25 | $-63.0M | $7.0M | ||
| Q2 25 | $-34.2M | $-4.2M | ||
| Q1 25 | $-163.2M | $19.0M | ||
| Q4 24 | $-86.8M | $53.1M | ||
| Q3 24 | $-27.1M | $20.0M | ||
| Q2 24 | $16.9M | $21.9M | ||
| Q1 24 | $-463.7M | $-12.1M |
| Q4 25 | -21.8% | 11.8% | ||
| Q3 25 | -7.4% | 3.9% | ||
| Q2 25 | -3.9% | -2.4% | ||
| Q1 25 | -21.2% | 11.3% | ||
| Q4 24 | -11.2% | 29.6% | ||
| Q3 24 | -3.3% | 11.7% | ||
| Q2 24 | 2.1% | 12.8% | ||
| Q1 24 | -60.4% | -7.3% |
| Q4 25 | 11.3% | 3.8% | ||
| Q3 25 | 16.0% | 3.9% | ||
| Q2 25 | 19.3% | 6.3% | ||
| Q1 25 | 22.7% | 4.0% | ||
| Q4 24 | 26.3% | 2.7% | ||
| Q3 24 | 23.3% | 1.8% | ||
| Q2 24 | 19.4% | 3.4% | ||
| Q1 24 | 18.5% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 4.43× | — | ||
| Q1 25 | 1.37× | 3.89× | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 2.39× | 5.35× | ||
| Q2 24 | 2.18× | 15.44× | ||
| Q1 24 | -4.21× | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
ACHC
| Acute Inpatient Psychiatric Facilities | $451.2M | 55% |
| Comprehensive Treatment Centers | $144.2M | 18% |
| Medicare | $113.7M | 14% |
| Residential Treatment Centers | $89.7M | 11% |
| Self Payor | $16.1M | 2% |
| Other Payor | $10.7M | 1% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
